OSUR

OraSure Technologies, Inc. Common Stock

OSUR
Closed
$4.28
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. The company is headquartered in Bethlehem, Pennsylvania and currently employs 500 full-time employees. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its products and services include OraQuick ADVANCE Rapid HIV 1/2 Antibody Test, OraQuick HIV Self-Test, Diagnostics Direct Syphilis Health Check, OraQuick Ebola Rapid Antigen Test, InteliSwab COVID-19 Rapid Test Pro, and SickleSCAN Test, among others. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers.
Country

US

CEO

Ms. Carrie Eglinton Manner

IPO date

1986

Employees

500

ISIN

US68554V1089

Key stats

Open

$4.16

Volume

298.91K

Market cap

$292.61M

Prev. close

$4.28

Impl / hst vl

-

Open interest

$0.00

$4.16

Day’s Range

$4.34

$2.33

52W Range

$4.58

Valuation

72
Valuation score
Undervalued
P/E
-
P/S
2.56
P/B
0.92
Current ratio
5.46
Debt / Equity
-0.56
ROE
-21.50%
Gross margin
42.27%
Income growth
16.03%
FCF growth
49.30

Analysts estimates

Consensus rating
Strong buy

The average rating from top 3 analysts indicates that stock may significantly outperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$5.10
The top 4 analysts forecasts that 12-month price may increase by 19.16%, with a low of $4.04 and a high of $6.30
$4.04
Low
$5.10
Avg
$6.30
High
Current price

Earnings

Q1 ‘26 revenue
$27.93M
Q1 ‘26 net income
-$22.38M
Revenue
Net income
Previous EPS
-$0.32
Estimate EPS
-$0.21
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply